AMRX NASDAQ
Amneal Pharmaceuticals, Inc.
1W: +8.6%
1M: +6.3%
3M: +12.1%
YTD: +66.0%
1Y: +101.7%
3Y: +495.5%
5Y: +276.7%
$21.44
+0.42 (+2.00%)
After Hours: $21.25 (-0.19, -0.89%)
Weekly Expected Move ±4.0%
$19
$20
$20
$21
$22
Credit Risk of going bust: lower than 58% of companies Debt: 29.4% of company value Bonds: $58.6M held by 128 funds, 178 bp over Treasuries → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.60 (down 97%), Amneal Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.79B against a stock market value of $6.71B.
Distance to default 5.91 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.39B (short-term plus half of long-term), stock volatility 35.6%; Altman Z 2.51. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $0.60 (down 97%), Amneal Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $2.79B against a stock market value of $6.71B.
Distance to default 5.91 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.39B (short-term plus half of long-term), stock volatility 35.6%; Altman Z 2.51. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
2 relationships2
As Filer
counterparties named
0
As Counterparty
mentioned by others
1
Rel. Types
2022-01-05
Earliest Filing
2022-01-05
Latest Filing
target: 2
Counterparties (Filed by AMRX)
2 relationshipsCompanies named in AMRX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Saol Therapeutics | — | target | Target of asset acquisition for baclofen franchise including LIORESAL and LYVISPAH | 2022-01-05 | View |
| Saol International Limited | — | target | Parent entity of Saol Therapeutics affiliated with the target company | 2022-01-05 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-23 | Exhibits | View | |
| 2026-08-10 | Material Agreement; Acquisition/Disposition; Financial Obligation; Unregistered Equity Sales; Regula | Agreement Acquisition | View |
| 2026-08-03 | Material Agreement | Agreement | View |
| 2026-07-31 | Shareholder Vote | View | |
| 2026-07-30 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-05-07 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-22 | Material Agreement; Earnings Release; Unregistered Equity Sales; Regulation FD; Exhibits | Agreement | View |
| 2026-02-27 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-02-03 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation | Agreement | View |
| 2026-01-28 | Other Events | View | |
| 2026-01-13 | Results of Operations and Financial Condition; Regulation FD Disclosure | View | |
| 2025-10-30 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-08-05 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-08-05 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-08-01 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-07-24 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-21 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-21 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-05-08 | Submission of Matters to a Vote of Security Holders | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR